Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
our study ıs desıgned as an observatıonal clınıcal study. the purpose ıs to compare the over reserve tests of the patıents before and after vaccıne, to determıne ıf the over reserve and fertılıty of women are affected by the vaccıne.women who applied to the vaccination outpatient clinic for the first dose of vaccine were included in the study.those who have never been vaccinated and have not had covid 19 infection were included in the study.antı ullerıan hormone level ıs the laboratory parameters that best showıng the ovary reserve today. ovarian reserve tests including amh were checked and their fertility was questioned and their information was recorded.
the same tests were repeated after the volunteers received 2 doses of vaccine. ın the power analysis, it was calculated that 104 volunteers should be included in the study.the study will be terminated when 104 volunteers are reached.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Gaziosmanpaşa
-
Istanbul, Gaziosmanpaşa, Turkey, 32225
- Gaziosmanpaşa Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- between 18-45 years old
- have ever had a covid vaccine
- not be infected with covid 19
Exclusion Criteria:
- pregnancy
- diagnosis of any kind of cancer
- oral contraceptive usage
- endometrioma
- PCOS
- menopause
- menstrual irregularity
- premature ovarian insufficiency
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pre-vaccine ovarian reserve and fertility status
Before vaccination, ovarian reserve tests and fertility status of 64 women will be examined and results will be recorded.After 2 doses of vaccination, ovarian reserve and fertility status of same 64 women will be examined and results will be recorded
|
volunteers will be expected to receive 2 doses of vaccine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ovarian reserve tests and fertility status of 74 women before and after vaccination
Time Frame: 6 months after receiving the 2nd dose of vaccine
|
before and after vaccination serum Amh level ng/ml
|
6 months after receiving the 2nd dose of vaccine
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AMH difference between vaccinated and unvaccinated groups
Time Frame: 6 months
|
AMH difference between vaccinated and unvaccinated groups
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GaziosmanpasaTREHm
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccine Adverse Reaction
-
NCT05546502CompletedVaccine Adverse Reaction | Vaccine Reaction
-
NCT04551248UnknownPneumococcal Vaccine Adverse Reaction
-
NCT05482282WithdrawnDiphtheria Vaccine Adverse Reaction | Tetanus Vaccine Adverse Reaction | Pertussis Vaccine Adverse Reaction | Haemophilus Influenzae Type B Vaccine Adverse Reaction | Hepatitis B Vaccine Adverse Reaction
-
NCT04770649TerminatedVaccine Adverse Reaction | Vaccine Response Impaired
-
NCT03400878CompletedVaccine Adverse Reaction | Vaccine Reaction | Infant Mortality | Heterologous Immunity | Infant Morbidity | Trained Immunity
-
NCT06180447Active, not recruitingVaccine Adverse Reaction
-
NCT03966391CompletedVaccine Adverse Reaction | Fear | Vaccination; Complications
-
NCT03966300TerminatedVaccine Adverse Reaction | Fear | Vaccination; Complications
Clinical Trials on sars cov 2 biontec vaccine
-
NCT05911087Not yet recruiting
-
NCT05952505Not yet recruitingMeasles | Rubella | Mumps | Varicella | SARS-CoV-2 Infection
-
NCT05112913Active, not recruiting
-
NCT04639466Completed
-
NCT05238649Active, not recruiting
-
NCT05633927CompletedHIV Infection | SARS-CoV-2 RNA Vaccines
-
NCT04932876RecruitingCovid19 | End Stage Kidney Disease | Vaccination | Kidney Transplantion
-
NCT04747522Active, not recruitingKidney Transplant Infection | SARS-CoV Infection
-
NCT04895475CompletedCovid19 | SARS-CoV Infection | Coronavirus | Humoral Acquired Immunodeficiency